BRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir

Reuters02-24

BRIEF-<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B <a href="https://laohu8.com/S/PBFS">Pioneer</a> Trial Of Pociredir

Feb 24 (Reuters) - Fulcrum Therapeutics Inc FULC.O:

FULCRUM THERAPEUTICS ANNOUNCES POSITIVE 12-WEEK RESULTS FROM THE 20 MG DOSE COHORT OF THE PHASE 1B PIONEER TRIAL OF POCIREDIR IN SICKLE CELL DISEASE
FULCRUM THERAPEUTICS INC - POCIRDIR WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS

Source text: ID:nGNX1Nswmk

Further company coverage: FULC.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613715749?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613715749","market":"fut","top_or_hot":-1,"title":"BRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B <a href=\"https://laohu8.com/S/PBFS\">Pioneer</a> Trial Of Pociredir</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>FULC.O</span>:</p><ul><li><p>FULCRUM THERAPEUTICS ANNOUNCES POSITIVE 12-WEEK RESULTS FROM THE 20 MG DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF THE PHASE 1B PIONEER TRIAL OF POCIREDIR IN SICKLE CELL DISEASE</p></li><li><p>FULCRUM THERAPEUTICS INC - POCIRDIR WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>ID:nGNX1Nswmk</span></p><p>Further company coverage: <span>FULC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B <a href=\"https://laohu8.com/S/PBFS\">Pioneer</a> Trial Of Pociredir</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>FULC.O</span>:</p><ul><li><p>FULCRUM THERAPEUTICS ANNOUNCES POSITIVE 12-WEEK RESULTS FROM THE 20 MG DOSE <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF THE PHASE 1B PIONEER TRIAL OF POCIREDIR IN SICKLE CELL DISEASE</p></li><li><p>FULCRUM THERAPEUTICS INC - POCIRDIR WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>ID:nGNX1Nswmk</span></p><p>Further company coverage: <span>FULC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUABRLG3:1","article_id":"2613715749","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613715749","pubTimestamp":1771934765,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of PociredirFeb 24 (Reuters) - Fulcrum Therapeutics Inc FULC.O:FULCRUM THERAPEUTICS ANNOUNCES POS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FULC":"Fulcrum Therapeutics","BK4007":"制药"},"translate_title":"BRIEF-Fulcrum Therapeutics宣布pociredir 1b期先锋试验20 Mg剂量队列的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":0.9},"content_text":"BRIEF-Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of PociredirFeb 24 (Reuters) - Fulcrum Therapeutics Inc FULC.O:FULCRUM THERAPEUTICS ANNOUNCES POSITIVE 12-WEEK RESULTS FROM THE 20 MG DOSE COHORT OF THE PHASE 1B PIONEER TRIAL OF POCIREDIR IN SICKLE CELL DISEASEFULCRUM THERAPEUTICS INC - POCIRDIR WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTSSource text: ID:nGNX1NswmkFurther company coverage: FULC.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613715749","isCrawlerRequest":true}